ERBB2 and neoplasm: We have previously shown that, within HER2+ early BC, HER2-enriched PAM50 tumours present significantly higher sTILs as compared with other PAM50 subtypes, both at baseline (10% vs 5%; P = 0.006) and at day 15 (20% vs 10%; P < 0.001)17.